Hong Wan Xing, Hu Michael S, Esquivel Mikaela, Liang Grace Y, Rennert Robert C, McArdle Adrian, Paik Kevin J, Duscher Dominik, Gurtner Geoffrey C, Lorenz H Peter, Longaker Michael T
Hagey Laboratory for Pediatric Regenerative Medicine, Division of Plastic Surgery, Department of Surgery, Stanford University School of Medicine , Stanford, California. ; Department of Radiology, Stanford University School of Medicine , Stanford, California. ; University of Central Florida College of Medicine , Orlando, Florida.
Hagey Laboratory for Pediatric Regenerative Medicine, Division of Plastic Surgery, Department of Surgery, Stanford University School of Medicine , Stanford, California. ; Department of Surgery, John A. Burns School of Medicine, University of Hawai'i , Honolulu, Hawai'i.
Adv Wound Care (New Rochelle). 2014 May 1;3(5):390-399. doi: 10.1089/wound.2013.0520.
Poor wound healing remains a significant health issue for a large number of patients in the United States. The physiologic response to local wound hypoxia plays a critical role in determining the success of the normal healing process. Hypoxia-inducible factor-1 (HIF-1), as the master regulator of oxygen homeostasis, is an important determinant of healing outcomes. HIF-1 contributes to all stages of wound healing through its role in cell migration, cell survival under hypoxic conditions, cell division, growth factor release, and matrix synthesis throughout the healing process. Positive regulators of HIF-1, such as prolyl-4-hydroxylase inhibitors, have been shown to be beneficial in enhancing diabetic ischemic wound closure and are currently undergoing clinical trials for treatment of several human-ischemia-based conditions. HIF-1 deficiency and subsequent failure to respond to hypoxic stimuli leads to chronic hypoxia, which has been shown to contribute to the formation of nonhealing ulcers. In contrast, overexpression of HIF-1 has been implicated in fibrotic disease through its role in increasing myofibroblast differentiation leading to excessive matrix production and deposition. Both positive and negative regulators of HIF-1 therefore provide important therapeutic targets that can be used to manipulate HIF-1 expression where an excess or deficiency in HIF-1 is known to correlate with pathogenesis. Targeting HIF-1 during wound healing has many important clinical implications for tissue repair. Counteracting the detrimental effects of excessive or deficient HIF-1 signaling by modulating HIF-1 expression may improve future management of poorly healing wounds.
伤口愈合不佳仍然是美国大量患者面临的一个重大健康问题。机体对局部伤口缺氧的生理反应在决定正常愈合过程的成败中起着关键作用。缺氧诱导因子-1(HIF-1)作为氧稳态的主要调节因子,是愈合结果的重要决定因素。HIF-1在整个愈合过程中通过其在细胞迁移、缺氧条件下的细胞存活、细胞分裂、生长因子释放和基质合成中的作用,对伤口愈合的各个阶段都有贡献。HIF-1的正向调节因子,如脯氨酰-4-羟化酶抑制剂,已被证明有助于促进糖尿病缺血性伤口的愈合,目前正在进行治疗几种基于人类缺血性疾病的临床试验。HIF-1缺乏以及随后对缺氧刺激无反应会导致慢性缺氧,这已被证明会导致不愈合溃疡的形成。相反,HIF-1的过度表达通过增加肌成纤维细胞分化导致过多的基质产生和沉积,与纤维化疾病有关。因此,HIF-1的正向和负向调节因子都提供了重要的治疗靶点,可用于在已知HIF-1过量或缺乏与发病机制相关的情况下调控HIF-1的表达。在伤口愈合过程中靶向HIF-1对组织修复具有许多重要的临床意义。通过调节HIF-1表达来对抗HIF-1信号过度或不足的有害影响,可能会改善未来对愈合不良伤口的管理。